(Q34787426)

4 August 2017

Japanese encephalitis vaccine in travelers (English)

1 reference

Japanese encephalitis virus

4 August 2017

0 references

Japanese encephalitis

1 reference

based on heuristic

inferred from title

Japanese encephalitis vaccine

1 reference

1 reference

Tomas Jelinek

1

1 reference

4 August 2017

1 July 2008

1 reference

Expert Review of Vaccines

4 August 2017

1 reference

4 August 2017

7

1 reference

4 August 2017

5

1 reference

4 August 2017

689-693

1 reference

A decade of Japanese encephalitis surveillance in Sarawak, Malaysia: 1997-2006.

4 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Japanese encephalitis--a plague of the Orient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

The natural history of Japanese encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Protection against Japanese encephalitis by inactivated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Control of Japanese encephalitis--within our grasp?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Japanese encephalitis: a Chinese solution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Further experience with Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Side-effects with Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Adverse reactions to Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Adverse reactions to Japanese encephalitis vaccine in travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-hu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.5.689

21 January 2018

Identifiers

DOI

10.1586/14760584.7.5.689

1 reference

4 August 2017

1 reference

PubMed ID

18564023